Chimerix Inc. (NASDAQ:CMRX) was up 2.4% during mid-day trading on Thursday . The company traded as high as $4.27 and last traded at $4.20, with a volume of 293,175 shares traded. The stock had previously closed at $4.10.

A number of equities research analysts recently issued reports on CMRX shares. Zacks Investment Research upgraded Chimerix from a “hold” rating to a “buy” rating and set a $5.25 price objective on the stock in a research report on Wednesday, May 11th. FBR & Co reiterated a “hold” rating on shares of Chimerix in a research report on Sunday, July 17th. Two research analysts have rated the stock with a sell rating, eleven have issued a hold rating, two have given a buy rating and one has given a strong buy rating to the stock. Chimerix has a consensus rating of “Hold” and an average target price of $16.98.

The stock’s 50-day moving average price is $4.03 and its 200 day moving average price is $5.51. The company’s market cap is $190.40 million.

Chimerix (NASDAQ:CMRX) last issued its earnings results on Monday, May 9th. The biopharmaceutical company reported ($0.57) earnings per share for the quarter, topping the consensus estimate of ($0.66) by $0.09. The firm earned $1.20 million during the quarter, compared to the consensus estimate of $2.79 million. Equities analysts anticipate that Chimerix Inc. will post ($2.06) EPS for the current fiscal year.

In other news, CEO M Michelle Berrey bought 13,188 shares of the company’s stock in a transaction that occurred on Friday, June 24th. The stock was bought at an average price of $3.69 per share, with a total value of $48,663.72. Following the acquisition, the chief executive officer now owns 258,821 shares of the company’s stock, valued at approximately $955,049.49. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Ernest Mario bought 10,000 shares of the company’s stock in a transaction that occurred on Friday, May 13th. The stock was purchased at an average cost of $4.53 per share, with a total value of $45,300.00. Following the acquisition, the director now directly owns 331,440 shares in the company, valued at approximately $1,501,423.20. The disclosure for this purchase can be found here.

A number of hedge funds and institutional investors have recently modified their holdings of the company. Morgan Stanley increased its position in shares of Chimerix by 96.7% in the fourth quarter. Morgan Stanley now owns 187,163 shares of the biopharmaceutical company’s stock valued at $1,674,000 after buying an additional 92,005 shares in the last quarter. Trexquant Investment LP increased its position in shares of Chimerix by 453.5% in the fourth quarter. Trexquant Investment LP now owns 131,184 shares of the biopharmaceutical company’s stock valued at $1,174,000 after buying an additional 107,484 shares in the last quarter. Finally, Jennison Associates LLC increased its position in shares of Chimerix by 67.9% in the fourth quarter. Jennison Associates LLC now owns 1,273,779 shares of the biopharmaceutical company’s stock valued at $11,400,000 after buying an additional 515,029 shares in the last quarter.

Chimerix, Inc a biopharmaceutical company dedicated to discovering, developing and commercializing oral antivirals. The Company’s lipid conjugate technology has developed its lead compound, brincidofovir (BCV, CMX001), which is in Phase III clinical development. It is clinical-stage nucleotide analog lipid-conjugate which has demonstrated potent antiviral activity and safety in convenient, orally administered dosing regimens.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.